UNSPSC 51271621: Bumecaine hydrochloride

This classification denotes an anesthetic agent C18H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PBE1H9OIFQ, chemically known as 1-butyl-2',4',6'-trimethyl-2-pyrrolidinecarboxanilide hydrochloride, but more generally known as bumecaine hydrochloride, which bears US NIH Compound Identifier 167785. Most nations, for tariff and trade purposes, schedule bumecaine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUMECAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCCCN1CCCC1C(=O)NC2C(CC(CC2C)C)C.CL.

UNSPSC 51271621 Bumecaine hydrochloride is a Commodity code representing local anesthetic pharmaceutical products, which state and local governments procure through cooperative purchasing agreements and direct supply arrangements for use in medical facilities, clinics, and emergency response operations. The code encompasses branded and generic formulations of this injectable anesthetic, typically sourced through established pharmaceutical wholesaler networks and subject to FDA approval, Good Manufacturing Practices certification, and Drug Supply Chain Security Act compliance. State and local procurement under this code flows primarily through multistate cooperative purchasing alliances and individual health department or public hospital system solicitations that bundle pharmaceuticals with other generic drugs and over-the-counter products to achieve volume pricing and supply security.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a proposal due date of March 26, 2026, serving participating state and local government facilities in Minnesota and Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), supported by compliance with administrative requirements, EDI capability, and fixed pricing terms; vendors must maintain comprehensive insurance coverage including $5 million commercial general liability per occurrence and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures. No specific set-aside or disadvantaged-enterprise restrictions apply to this RFP based on available documentation, and the contract term extends two years for new responders with optional extensions at MMCAP's discretion.